APA (7th ed.) Citation

A, R., CD, C., LM, R., AF, C., L, R., ZL, Z., . . . O, A. (2018). EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP). Targeted oncology, 13(5), 621. https://doi.org/10.1007/s11523-018-0594-x

Chicago Style (17th ed.) Citation

A, Ruiz-Patiño, et al. "EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)." Targeted Oncology 13, no. 5 (2018): 621. https://doi.org/10.1007/s11523-018-0594-x.

MLA (9th ed.) Citation

A, Ruiz-Patiño, et al. "EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)." Targeted Oncology, vol. 13, no. 5, 2018, p. 621, https://doi.org/10.1007/s11523-018-0594-x.